Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Blanca I. Restrepo has a total of 300 co-authors. Here are the top co-authors by number of shared publications:

  • Jordi B. Torrelles

    Texas Biomedical Research Institute

    7 shared publications
  • Larry S. Schlesinger

    Host-Pathogen Interactions and Population Health Programs, Texas Biomedical Research Institute, San Antonio, TX, USA

    6 shared publications
  • Larry S. Schlesinger

    Texas Biomedical Research Institute, San Antonio, TX, USA

    6 shared publications
  • Doris Ayala

    School of Public Health, University of Texas Health Science Center at Houston, Brownsville, USA

    5 shared publications
  • Francisco Mora-Guzmán

    Secretaria de Salud de Tamaulipas, Reynosa 88630, Matamoros 87370 and Ciudad Victoria 87000, Tamaulipas, México

    5 shared publications
  • Jordi B. Torrelles

    Population Health and Host Pathogens Interactions Programs and International Center for the Advancement of Research & Education (I•CARE), Texas Biomedical Research Institute, San Antonio, USA

    5 shared publications

Latest Publications

  • Open Access

    Frailty as a Framework to Understand Tuberculosis Severity, Recovery, and Sequelae

    by Yoscelina E Martinez-Lopez, Benjamin W Black, Jessica Lee, Brian J Buta, Lisa Y Armitige, William A Fountain, Rafael Samper, Aanand D Naik, Joanne Turner, Qian-Li Xue, et al.

    Tuberculosis (TB) causes profound systemic illness, and many survivors experience long-term sequelae associated with disability and premature mortality. Current TB severity indicators capture isolated aspects of disease and may not reflect the integrated physiological impact of infection on the host. Frailty, a multidimensional syndrome characterized by reduced physiological reserve and increased vulnerability to stressors, predicts adverse outcomes and guides clinical management in geriatrics. We propose frailty as an integrative framework for understanding the systemic effects of TB across the life course, encompassing disease severity, recovery, and long-term sequelae. We discuss biological mechanisms through which Mycobacterium tuberculosis infection may erode physiological reserve and promote frailty, including inflammation and metabolic and endocrine dysregulation. We further consider how frailty assessment could improve risk stratification and guide individualized supportive care to mitigate post-TB sequelae. Unlike aging-related frailty, TB-associated frailty may provide a unique opportunity to study mechanisms of resilience and recovery following severe infection. Frailty offers a multidimensional framework for understanding the systemic impact of tuberculosis (TB) beyond conventional disease severity measures, with potential to improve risk stratification, guide individualized supportive care, and evaluate recovery and post-TB sequelae.

  • Open Access

    Accuracy of the Phenotypic 1G Test to Detect Mycobacterium tuberculosis and Drug Resistance From Sputa in the US-Mexico Border

    by Mia Aguirre, Doris Ayala, Juan Ignacio Garcia, Yoscelina E Martinez-Lopez, Amberlee D Hicks, Nadine Chacon, Ashley Gay-Cobb, Alyssa Schami, Selena Zavala-Perez, Ilse A Dominguez-Trejo, et al.

    Background: With >10 million new tuberculosis (TB) cases per year, a limitation to TB control is the lack of simple and accurate tests for diagnosis and drug susceptibility testing (DST) in endemic regions. We evaluated the accuracy of the first-generation, low-complexity phenotypic TB test (1G test), designed for simultaneous Mycobacterium tuberculosis (Mtb) detection and resistance to isoniazid, rifampicin, and moxifloxacin, suitable for resource-limited settings. Methods: A cross-sectional study was conducted with sputa from 426 possible pulmonary TB cases from 2 small Mexican cities bordering Texas. The 1G test was compared against phenotypic TB detection tests in the region, specifically acid-fast bacilli smear microscopy and Mycobacteria Growth Indicator Tube (MGIT) culture, as well as MGIT-DST for resistance to isoniazid, rifampicin, and moxifloxacin. Results: The 1G test demonstrated ≥98% sensitivity for Mtb detection; 100% sensitivity and 91% (rifampicin), 94% (isoniazid), and 97% (moxifloxacin) specificity for DST; and less contamination than the MGIT (3.5% vs 8.1%, P < .05). The 1G test time to detection of Mtb and simultaneous DST was 17 days, while the MGIT-DST required 2 steps: 7 days for Mtb detection plus 14 more days for DST (21 days total). Our study site drug-resistant TB prevalence was 14% when testing all consecutively enrolled participants vs 6% by passive reporting. Conclusions: The 1G test is a low-complexity phenotypic TB diagnostic method that is a practical replacement to current culture-based tests. Future studies are warranted to evaluate implementation of the 1G test in decentralized clinics that lack molecular tools, resources, and expertise.

  • Open Access

    Human alveolar macrophage function is impaired in tuberculosis contacts with diabetes

    by Léanie Kleynhans, Carine Kunsevi-Kilola, Happy Tshivhula, Tariq Webber, Alana Keyser, Nicole Prins, Candice I. Snyders, Ayanda Shabangu, Virginie Rozot, Martin Kidd, et al.


  • Open Access

    Human alveolar macrophage response to Mycobacterium tuberculosis: immune characteristics underlying large inter-individual variability

    by Wolfgang Sadee, Ian H. Cheeseman, Audrey Papp, Maciej Pietrzak, Michal Seweryn, Xiaofei Zhou, Shili Lin, Amanda M. Williams, Mark D. Wewers, Heather M. Curry, et al.

    Mycobacterium tuberculosis (M.tb) infection infects human alveolar macrophages (HAMs). In freshly isolated HAMs from 28 healthy adults, we observe large inter-individual differences in bacterial uptake and growth, with tenfold variation in M.tb load by 72 h. While M.tb infection triggers expression changes of numerous host mRNAs, we examined which genes are most variably expressed (VE genes) between donors, as potential biomarkers of individual tuberculosis (TB) risk. The HAM RNA transcriptome following infection revealed thousands of differentially expressed (DE) genes and differential secretion of 25/27 proteins. Yet only 324 DE genes represent VE genes detected exclusively among DE genes in infected cells. Of 36 DE genes detected at all time points (2, 24, and 72 h), 14 are VE genes, indicating early emergence of the VE gene profile. 9/27 DE proteins following infection were encoded by VE genes. Systems analysis of VE RNAs identified a top-scoring network anchored by IL1B, involved in TB immune response. Independent M.tb-HAM transcriptome results from a TB-endemic region show significant overlap in DE genes, including VE genes identified in the main study. Thus, we identify a VE gene network activated upon M.tb-HAM infection with high inter-person variability, guiding studies on determining individual risk of M.tb infection and/or disease.


  • Open Access

    Interaction between type 2 diabetes and past COVID-19 on active tuberculosis

    by Liz E. Calles-Cabanillas, Genesis P. Aguillón-Durán, Doris Ayala, José A. Caso, Miguel Garza, Mateo Joya-Ayala, America M. Cruz-Gonzalez, Raul Loera-Salazar, Ericka Prieto-Martinez, Javier E. Rodríguez-Herrera, et al.

    The global setback in tuberculosis (TB) prevalence and mortality in the post-COVID-19 era has been partially attributed to pandemic-related disruptions in healthcare systems. The additional biological contribution of COVID-19 to TB is less clear. The goal of this study was to determine if there is an association between COVID-19 in the past 18 months and a new TB episode, and the role played by type 2 diabetes mellitus (DM) comorbidity in this relationship. A cross-sectional study was conducted among 112 new active TB patients and 373 non-TB controls, identified between June 2020 and November 2021 in communities along the Mexican border with Texas. Past COVID-19 was based on self-report or positive serology. Bivariable/multivariable analysis were used to evaluate the odds of new TB in hosts with past COVID-19 and/or DM status. The odds of new TB were higher among past COVID-19 cases vs. controls, but only significant among DM patients (aOR 2.3). The odds of TB in people with DM was 2.7-fold higher among participants without past COVID-19 and increased to 7.9-fold among those with past COVID-19. DM interacts with past COVID-19 synergistically to magnify the risk of TB. Latent TB screening and prophylactic treatment, if positive, is recommended in past COVID-19 persons with DM. Future studies are warranted with a longitudinal design and larger sample size to confirm our findings.


  • Open Access

    Human Alveolar Macrophage Function is Impaired in Tuberculosis Contacts With Diabetes

    by Katharina Ronacher, Léanie Kleynhans, Carine Kunsevi-Kilola, Happy Tshivhula, Tariq Webber, Alana Keyser, Nicole Prins, Candice Snyders, Ayanda Shabangu, Virginie Rozot, et al.

    Type 2 diabetes (T2D) increases susceptibility to tuberculosis (TB) with the underlying mechanisms remaining unknown. To determine whether immune dysfunction in the lung contributes to TB susceptibility, we obtained paired human alveolar macrophages (HAMs) and monocyte-derived macrophages (MDMs) from TB-exposed individuals with/without T2D. Upon infection with Mycobacterium tuberculosis (M.tb), T2D-HAMs had more M.tb growth and produced more TNF. There were fewer neutrophils in the bronchoalveolar lavage of T2D patients which was inversely correlated with M.tb growth. Both T2D-HAMs and MDMs expressed less CD32, with T2D patients having fewer M1-like MDMs. T2D-MDMs produced less IL-1RA and CSF2. Overall M.tb-induced gene expression was delayed in T2D-HAMs, but genes involved in negative regulation of neutrophil migration were upregulated. T2D-HAM DNA was hypermethylated compared to control HAMs, however genes linked to TNF signalling were hypomethylated. We show here the first in-depth analysis of T2D-HAMs providing an explanation for more severe TB in T2D patients.


  • Open Access

    Picking the low-hanging fruit: the cost-effectiveness of opportunistic diabetes screening during tuberculosis contact investigations on the Texas–Mexico border

    by Robert A McGowan, Henry Shelton Brown, Juan Carlos Lopez-Alvarenga, Blanca I Restrepo

    Objective: There is a known association between type 2 diabetes (diabetes) and tuberculosis (TB), and TB clinics have become hubs for new diabetes diagnosis among active patients with TB. However, despite the potential to identify diabetes patients, resources limit diabetes screening opportunities to close TB contacts. We assessed the cost-effectiveness of adding opportunistic screening for diabetes during the routine TB contact investigations conducted at TB clinics. Research design and methods: We used a Markov-based model to simulate the costs of diabetes screening, management and health outcomes, including the incidence of complications and death. All costs were considered from a health system perspective. One-way sensitivity analyses were conducted to assess the robustness of the results to various assumptions. Interventions that fall below US$50 000 per quality-adjusted life years (QALYs) are commonly considered very cost-effective, while those between $50 000 and $100 000 are considered moderately cost-effective. Results: Simulation of diabetes screening among TB contacts resulted in not only increased survival and reduced complications but also increased costs of diabetes management. The resulting incremental cost-effectiveness ratio was $32 642 per QALY added, which is well within commonly used willingness-to-pay thresholds for cost-effectiveness. Compared with no screening, screening increased the costs by $8633 and resulted in an increase in QALYs by 0.26 per patient. Conclusions: In the base case analysis, screening was very cost-effective given that none of the sensitivity analyses resulted in a cost-effectiveness ratio above $50 000 per QALY. Our results indicate that the expansion of diabetes screening in TB clinics is a cost-effective strategy to improve health outcomes.


  • Open Access

    Diagnostic Accuracy of Nanopore Sequencing for Detecting Mycobacterium tuberculosis and Drug-Resistant Strains: A Systematic Review and Meta-Analysis

    by Timothy Hudson David Culasino Carandang, Dianne Jaula Cunanan, Gail S. Co, John David Pilapil, Juan Ignacio Garcia, Blanca I. Restrepo, Marcel Yotebieng, Jordi B. Torrelles, Kin Israel Notarte

    Tuberculosis (TB), caused by Mycobacterium tuberculosis (MTB) infection, remains a significant public health threat. The timeliness, portability, and capacity of nanopore sequencing for diagnostics can aid in early detection and drug susceptibility testing (DST), which is crucial for effective TB control. This study synthesized current evidence on the diagnostic accuracy of the nanopore sequencing technology in detecting MTB and its DST profile. A comprehensive literature search in PubMed, Scopus, MEDLINE, Cochrane, EMBASE, Web of Science, AIM, IMEMR, IMSEAR, LILACS, WPRO, HERDIN Plus, MedRxiv, and BioRxiv was performed. Quality was assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 tool. Pooled sensitivity, specificity, predictive values (PV), diagnostic odds ratio (DOR), and area under the curve (AUC) were calculated. Thirty-two studies were included; 13 addressed MTB detection only, 15 focused on DST only, and 4 examined both MTB detection and DST. No study used Flongle or PromethION. Seven studies were eligible for meta-analysis on MTB detection and five for DST; studies for MTB detection used GridION only while those for DST profile used MinION only. Our results indicate that GridION device has high sensitivity [88.61%; 95% CI (83.81–92.12%)] and specificity [93.18%; 95% CI (85.32–96.98%)], high positive predictive value [94.71%; 95% CI (89.99–97.27%)], moderately high negative predictive value [84.33%; 95% CI (72.02–91.84%)], and excellent DOR [107.23; 95% CI (35.15–327.15)] and AUC (0.932) in detecting MTB. Based on DOR and AUC, the MinION excelled in detecting pyrazinamide and rifampicin resistance; however, it underperformed in detecting isoniazid and ethambutol resistance. Additional studies will be needed to provide more precise estimates for MinION’s sensitivity in detecting drug-resistance, as well as DOR in detecting resistance to pyrazinamide, streptomycin, and ofloxacin. Studies on detecting resistance to bedaquiline, pretomanid, and linezolid are lacking.

  • Open Access

    High all-cause mortality and increasing proportion of older adults with tuberculosis in Texas, 2008–2020

    by Belinda A. Medrano, Miryoung Lee, Gretchen Gemeinhardt, Lana Yamba, Blanca I. Restrepo

    Pulmonary tuberculosis (PTB) elimination efforts must consider the global growth of the ageing population. Here we used TB surveillance data from Texas, United States (2008–2020; total n = 10656) to identify unique characteristics and outcomes in older adults (OA, ≥65 years) with PTB, compared to young adults (YA, 18–39 years) or middle-aged adults (40–64 years). We found that the proportion of OA with PTB increased from 15% in 2008 to 24% in 2020 (trend p < 0.05). Diabetes was highly prevalent in OA (32%) but not associated with adverse outcomes. Death was 13-fold higher in OA compared to YA and was 7% at the time of diagnosis which suggests diagnostic delays. However, once TB was suspected, we found no differences in culture, smear, or nucleic acid detection of mycobacteria (although less lung cavitations) in OA. During treatment, OA had less drug-resistant TB, few adverse reactions and adhered with TB treatment. We recommend training healthcare workers to ‘think TB’ in OA, for prompt treatment initiation to diminish deaths. Furthermore, OA should be added as a priority group to the latent TB treatment guidelines by the World Health Organization, to prevent TB disease in this highly vulnerable group.


  • Open Access

    Tuberculosis presentation and outcomes in older Hispanic adults from Tamaulipas, Mexico

    by Belinda A. Medrano, Miryoung Lee, Gretchen Gemeinhardt, Javier E. Rodríguez-Herrera, Moncerrato García-Viveros, Blanca I. Restrepo

    Older people are at high risk of developing and dying from pulmonary infections like tuberculosis (TB), but there are few studies among them, particularly in Hispanics. To address these gaps, we sought to identify host factors associated with TB and adverse treatment outcomes in older Hispanics by conducting a cross-sectional study of TB surveillance data from Tamaulipas, Mexico (2006–2013; n = 8381). Multivariable logistic regressions were assessed for older adults (OA ≥65 years) when compared to young (YA, 18–39 years) and middle-aged adults (40–64 years). We found that the OA had features associated with a less complicated TB (e.g., lower prevalence of extra-pulmonary TB and less likely to abandon treatment or have drug resistant TB), and yet, were more likely to die during TB treatment (adj-OR 3.9, 95% 2.5, 5.25). Among the OA, excess alcohol use and low body mass index increased their odds of death during TB treatment, while a higher number of reported contacts (social support) was protective. Diabetes was not associated with adverse outcomes in OA. Although older age is a predictor of death during TB disease, OA are not prioritized by the World Health Organization for latent TB infection screening and treatment during contact investigations. With safer, short-course latent TB infection treatment available, we propose the inclusion of OA as a high-risk group in latent TB management guidelines.